Combining medication with a balanced diet and exercise routine is often crucial to ensure the best outcomes
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand name Mounjaro), chronic weight management (under the brand name Zepbound), and most recently in 2024, for the treatment of adults with moderate-to-severe obstructive sleep apnea who have obesity or are overweight with at least one weight-related comorbidity
Otherwise, I started using the gym in my building four times a week walking uphill
Not in Parkinsons, but two years ago another large study suggested that GLP-1R agonist use was associated with lower mortality than other diabetes treatments
Prompt care can help prevent vision loss and maintain your eyesight
En los ensayos clnicos publicados, la tirzepatida (Zepbound) mostr una prdida de peso promedio mayor que la semaglutida